Latest Articles
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire
Acrivon Therapeutics Announces FDA has Granted Breakthrough GlobeNewswire
Published: Feb. 5, 2025, 1:19 p.m.
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer The Manila Times
Published: Feb. 5, 2025, 1:07 p.m.
An Echo Press Editorial: 8 essential ways to lower stroke risk - Alexandria Echo Press
An Echo Press Editorial: 8 essential ways to lower stroke risk Alexandria Echo Press
Published: Feb. 5, 2025, 1:04 p.m.
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status - StockTitan
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status StockTitan
Published: Feb. 5, 2025, 1 p.m.
Bindi Irwin Opens Up About Her Decade-Long Battle With Endometriosis - Evrim Ağacı
Bindi Irwin Opens Up About Her Decade-Long Battle With Endometriosis Evrim Ağacı
Published: Feb. 5, 2025, 12:29 p.m.
Correlation of ferritin and glutathione peroxidase 4 (GPX4) level as a marker of ferroptosis process in endometrioma - Nature.com
Correlation of ferritin and glutathione peroxidase 4 (GPX4) level as a marker of ferroptosis process in endometrioma Nature.com
Published: Feb. 5, 2025, 12:28 p.m.
Endometriosis support group set up in Hartlepool due to long waits - hellorayo.co.uk
Endometriosis support group set up in Hartlepool due to long waits hellorayo.co.uk
Published: Feb. 5, 2025, 12:27 p.m.
Endometriosis support group set up in Hartlepool due to long waits - Rayo
Endometriosis support group set up in Hartlepool due to long waits Rayo
Published: Feb. 5, 2025, 12:23 p.m.
Serac Healthcare Advances Non-Invasive Endometriosis Imaging Test Following FDA Meeting - Femtech Insider
Serac Healthcare Advances Non-Invasive Endometriosis Imaging Test Following FDA Meeting Femtech Insider
Published: Feb. 5, 2025, 12:02 p.m.
Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron - Nature.com
Targeting the splicing factor SNRPB inhibits endometrial cancer progression by retaining the POLD1 intron Nature.com
Published: Feb. 5, 2025, 11:37 a.m.
Link copied to clipboard!